Long-term follow-up of hepatitis B e antigen-negative patients treated with peginterferon alpha-2a: progressive decrease in hepatitis B surface antigen in responders
Tarih
2012Yazar
Boucher, Charles A.
Pinarbasi, Binnur
Janssen, Harry L. A.
van Vuuren, Anneke J.
Hansen, Bettina E.
Ferenci, Peter
Rijckborst, Vincent
Akdogan, Meral
ter Borg, Martijn J.
Simon, Krzysztof
Flisiak, Robert
AKARCA, ULUS SALİH
Raptopoulou-Gigi, Maria
Verhey, Elke
Üst veri
Tüm öğe kaydını gösterÖzet
Objective Peginterferon (PEG-IFN) is considered as a first-line treatment option for hepatitis B e antigen (HBeAg)-negative chronic hepatitis B. We aimed to evaluate the long-term response to PEG-IFN in HBeAg-negative patients.
Koleksiyonlar
- Makale [92796]